Pharma firm makes RSV vaccine candidate breakthrough with artificial intelligence

By Millie Turner Biopharmaceutical firm Poolbeg Pharma has found a number of RSV vaccine candidates via artificial intelligence (AI), in a landmark move in finding a treatment for the virus. The London-listed company has prioritised candidates with existing early-stage clinical data, which could be repositioned into novel treatments for RSV infection. Candidates with solid safety data in humans are well positioned to rapidly enter a clinical trial to generate early human efficacy data for RSV, the company announced on Wednesday. RSV, which inflames the smallest airways in the lungs, can be dan…

Read More